$52.5 Million for Non-Invasive Nerve Stimulation
Nervonik has closed a $52.5 million Series B round to advance its non-invasive neuromodulation platform. The company's technology uses targeted electrical stimulation of peripheral nerves to treat chronic pain and neurological disorders — without surgery, implants, or pharmaceuticals.
The Technology
Nervonik's approach differs from traditional transcutaneous electrical nerve stimulation (TENS) in several key ways:
- Precision targeting: AI-guided electrode placement that adapts to individual anatomy
- Closed-loop feedback: Real-time monitoring of nerve response to optimize stimulation parameters
- Multi-nerve protocol: Ability to stimulate multiple nerve pathways simultaneously for complex pain conditions
Clinical Applications
The company is pursuing FDA clearance for several indications:
- Chronic low back pain — the largest addressable market in pain medicine
- Peripheral neuropathy — particularly diabetic neuropathy
- Post-surgical pain management — as an opioid-sparing alternative
Market Context
The global neuromodulation market is projected to exceed $15 billion by 2030. Nervonik's non-invasive approach could capture significant share by offering a lower-risk, lower-cost alternative to implantable devices from companies like Medtronic and Abbott.
Investor Interest
The round attracted both healthcare-specialist VCs and crossover funds, signaling confidence that non-invasive neuromodulation is moving from experimental to standard-of-care territory.
